We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+7.34%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.2B
AUM Growth
-$238M
(-17%)
Cap. Flow
-$147M
Cap. Flow
% of AUM
-12.32%
Top 10 Holdings %
Top 10 Hldgs %
60.4%
Holding
78
New
16
Increased
22
Reduced
29
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Inspire Medical Systems
INSP
|
+$23.6M |
| 2 |
HCA Healthcare
HCA
|
+$14.7M |
| 3 |
Bio-Techne
TECH
|
+$12.4M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$11.9M |
| 5 |
Krystal Biotech
KRYS
|
+$10.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$42.8M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$36.3M |
| 3 |
GSK
GSK
|
+$30.5M |
| 4 |
Natera
NTRA
|
+$20.7M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
+$17.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.99% |
| 2 | Miscellaneous | 20.84% |
| 3 | Communication Services | 0.66% |
| 4 | Financials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Protagonist Therapeutics
PTGX
$9.34B
| $3.17M | 0.26% |
+114,659
| New | +$2.87M |
|
52
Biohaven
BHVN
$2.33B
| $3.14M | 0.26% |
131,103
-54,492
| -29% | -$938K |
|
|
PRTK
53
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $2.93M | 0.25% |
1,327,857
+689,383
| +108% | +$1.43M |
|
54
Waters Corp
WAT
$40.7B
| $2.91M | 0.24% |
+10,928
| New | +$3.04M |
|
55
Revvity
RVTY
$14.4B
| $2.53M | 0.21% |
21,314
+8,979
| +73% | +$1.1M |
|
56
Black Diamond Therapeutics
BDTX
$128M
| $2.16M | 0.18% |
+427,317
| New | +$873K |
|
|
GOCO
57
DELISTED
GoHealth
GOCO
| $2.07M | 0.17% |
104,820
-20,233
| -16% | -$318K |
|
|
XOMA
58
DELISTED
Xoma
XOMA
| $1.7M | 0.14% |
89,950
| – | – |
|
59
Evolus
EOLS
$587M
| $1.66M | 0.14% |
228,679
+7,128
| +3% | +$61.5K |
|
60
argenx
ARGX
$64B
| $1.62M | 0.14% |
4,154
+318
| +8% | +$125K |
|
61
Zai Lab
ZLAB
$2.93B
| $1.53M | 0.13% |
55,176
-116,823
| -68% | -$3.82M |
|
62
Elevance Health
ELV
$85.5B
| $1.03M | 0.09% |
2,315
-18,300
| -89% | -$8.44M |
|
|
AFMD
63
DELISTED
Affimed
AFMD
| $1M | 0.08% |
167,668
-20,710
| -11% | -$166K |
|
64
Gossamer Bio
GOSS
$83.2M
| $900K | 0.08% |
749,697
-602,368
| -45% | -$750K |
|
|
JBIO
65
Jade Biosciences
JBIO
$1.33B
| $862K | 0.07% |
1,435
| – | – |
|
66
UroGen Pharma
URGN
$2.13B
| $774K | 0.06% |
+74,797
| New | +$825K |
|
|
WHWK
67
Whitehawk Therapeutics
WHWK
$263M
| $697K | 0.06% |
101,918
| – | – |
|
68
AC Immune
ACIU
$263M
| $368K | 0.03% |
124,589
| – | – |
|
69
ARS Pharmaceuticals
SPRY
$586M
| $327K | 0.03% |
+48,788
| New | +$326K |
|
|
KYNB
70
PUT
Kyntra Bio
KYNB
$32.5M
| $105K | 0.01% |
+1,552
| New | +$642K |
|
|
KYNB
71
Kyntra Bio
KYNB
$32.5M
| $15.1K | ﹤0.01% |
+224
| New | +$92.6K |
|
|
AMED
72
DELISTED
Amedisys
AMED
| – | – |
-224,263
| Closed | -$16.5M |
|
73
Avantor
AVTR
$9.86B
| – | – |
-717,614
| Closed | -$15.2M |
|
|
74
Biogen
BIIB
$32.3B
| – | – |
-153,774
| Closed | -$42.8M |
|
75
Guardant Health
GH
$21.7B
| – | – |
-483,098
| Closed | -$11.3M |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
GIA
MFM
Eversept Partners's Q2 2023 Portfolio in Review
As of Q2 2023, Eversept Partners held 78 positions worth $1.2B, down 17% from $1.43B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Eversept Partners withdrew a net $147M in Q2 2023, closing 7 positions and reducing 29 holdings. Its most notable exit was Biogen, an estimated $42.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Communication Services.
Against the trend, Eversept Partners opened a new position in Inspire Medical Systems worth $26.8M.
- Eversept Partners's largest Q2 2023 buy was Inspire Medical Systems: 82,445 shares worth $26.8M.
- Eversept Partners added most to HCA Healthcare in Q2 2023, an estimated $14.7M increase.
- Eversept Partners's biggest Q2 2023 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $36.3M.
- Eversept Partners fully exited Biogen in Q2 2023, selling an estimated $42.8M.
- Eversept Partners's ten largest holdings make up 60% of its $1.2B portfolio in Q2 2023.
- Eversept Partners opened 16 new positions and closed 7 in Q2 2023.
- Eversept Partners's portfolio value fell 17% quarter-over-quarter to $1.2B.
Based on Eversept Partners's 13F filing for Q2 2023, filed 14 Aug 2023.